Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management

American Journal of Hematology, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

ABSTRACT Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis The presence of IgM protein associated ≥ 10% clonal cells in bone marrow confirms the diagnosis. L265P mutation MYD88 detectable more than 90% patients found most MGUS patients. not required for Risk Stratification Age, albumin, hemoglobin level, platelet count, β 2 microglobulin, Lactate dehydrogenase (LDH), concentrations are characteristics that predictive outcomes. Risk‐Adapted Therapy Not all who fulfill WM criteria require therapy; these can be observed until symptoms develop. Rituximab‐monotherapy inferior to combination regimens. Recommended first‐line therapy chemoimmunotherapy or covalent Bruton tyrosine kinase inhibitor. preferred Mayo Clinic induction either rituximab bendamustine (without maintenance) zanubrutinib. Management Refractory Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, pirtobrutinib, carfilzomib, lenalidomide, bendamustine, venetoclax have been shown activity relapsed WM. Given WM's natural history, reduction toxicity an important part treatment selection. Most succumb causes unrelated macroglobulinemia.

Язык: Английский

---

Advances in classification and treatment of primary cutaneous lymphomas

Annals of Hematology, Год журнала: 2025, Номер unknown

Опубликована: Март 25, 2025

Язык: Английский

---

CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy

Clinical Reviews in Allergy & Immunology, Год журнала: 2024, Номер 66(3), С. 328 - 362

Опубликована: Июль 12, 2024

Язык: Английский

---

Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis

Anti-Cancer Agents in Medicinal Chemistry, Год журнала: 2024, Номер 25(1), С. 42 - 51

Опубликована: Авг. 28, 2024

Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell therapy as a novel immunotherapy treat malignant cells faces numerous challenges is in its early phase. To evaluate this possibility, we aimed review meta-analyze the related clinical trials systematically.

Язык: Английский

---

Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(17), С. 5117 - 5117

Опубликована: Авг. 28, 2024

Background/Objectives: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many them become platelet transfusion-dependent. Eltrombopag thrombopoietin agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully patients with bone marrow failure immune (ITP). Its role managing other cytopenias CAR-T cell-treated scarcely addressed. Our aim was report the safety efficacy this approach included Spanish Group for Hematopoietic Transplantation Cellular Therapy (GETH-TC) registry. Methods: This retrospective, multicenter, observational study. Patients who developed transfusion dependence subsequently cells received eltrombopag improve counts were recruited 10 hospitals. Results: Thirty-eight enrolled followed up median (interquartile range [IQR]) 175 (99, 489) days since infusion. At moment indicated, 18 had another severe cytopenia, while 8 pancytopenia. After 32 (14, 38) on eltrombopag, 29 (76.3%) recovered independence. The number units transfused correlated time needed restore higher than 20 × 109/L (Rho = 0.639, p < 0.001). Non-responders required more (58 [29, 69] vs. 12 [6, 26] responders, 0.002). Nineteen out twenty-three (82.6%) from neutropenia 22 (11, 31) eltrombopag. Twenty-nine thirty-five (82.9%) red blood (RBC) independence (17, 44) days. Seven all lineages treatment. No thromboembolic events reported. Only two transient toxicities (cholestasis, hyperbilirubinemia) reported during treatment, none compelled permanent drug withdrawal. Conclusions: could be safely manage patients.

Язык: Английский

---

Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy

Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 181, С. 117753 - 117753

Опубликована: Дек. 1, 2024

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, its effectiveness against solid tumors remains constrained by challenges such as exhaustion, limited persistence, and off-target effects. These highlight critical gaps in current CAR-T cell therapeutic strategies, particularly for tumor applications. Circular RNAs (circRNAs) represent a transformative class non-coding RNAs, known their exceptional stability precise regulatory functions, positioning them promising candidates enhancing next-generation therapies. Notably, circRNAs can bridge gap between preclinical research clinical application offering innovative solutions to overcome technical hurdles improve outcomes. Despite potential, remain underexplored therapies tumors, presenting significant opportunity innovation. The mechanisms through which modulate specificity are not yet fully understood, challenges, achieving efficient targeted circRNA delivery, still need be addressed. This review highlights importance integrating into enhance specificity, minimize effects, durability. By emphasizing potential identifying key gaps, this provides roadmap advancing setting stage next generation personalized cancer treatments.

Язык: Английский

---

Research progress on gene mutations and drug resistance in leukemia

Drug Resistance Updates, Год журнала: 2024, Номер 79, С. 101195 - 101195

Опубликована: Дек. 27, 2024

Язык: Английский

---